The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.

NCT06274385 | Recruiting

• 1 other identifier: 2311010178
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC on supramaximal performance and recovery. Therefore, the purpose of this study is to examine the effects of an acute dose of BRC on repeated-sprint cycling performance and recovery.

Conditions

Nutraceuticals

Keywords

betalains; beetroot; repeated sprint performance; supplement

Outcome Measures

Primary Outcomes (2)

• Repeated Sprint Performance

  Absolute and relative measures of peak, average, and minimum power (Watts). Also, the time to peak power and average power during the first and second half of each 30 s sprint.

  Each data point will be assessed immediately after each Wingate sprint

• Repeated Sprint Performance

  Fatigue index (%)

  Each data point will be assessed immediately after each Wingate sprint

Secondary Outcomes (1)

• Neuromuscular Fatigue

  Pre-repeated sprint exercise, immediately post-repeated sprint exercise, and 5 minutes post-repeated sprint exercise

Study Arms (2)

Betalain-rich Concentrate

EXPERIMENTAL

A single dose of a BRC supplementation

Dietary Supplement: Betalain-rich concentrate (AltRed)

Placebo

PLACEBO COMPARATOR

A single dose of a placebo

Other: Placebo

Interventions

Betalain-rich concentrate (AltRed) DIETARY_SUPPLEMENT

A single dose of 100 mg (2 x 50 mg) 120 min before exhaustive exercise. Supplement instructions: All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container. The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth.

Betalain-rich Concentrate

Placebo OTHER

A single dose (2 x empty capsules) 120 min before exhaustive exercise. Supplement instructions: All treatments will be administered in similar capsules (smell, color, and size) to ensure both the participants and researcher are blinded to the treatment. All treatments will be administered in an opaque lidded container. The participants will be instructed to close their eyes and carefully open the container, keeping their heads forward. They will be asked to place the container to their lips, tipping the container to pour the contents into their mouth. Immediately after, they will be instructed to drink water to help them swallow the pill and instructed not to chew or manipulate the pill inside their mouth.

Placebo

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, recreationally active males and females
• Aged 18-40
• Free of disease or injury

You may not qualify if:

• Have any musculoskeletal injuries that could be made worse by participating in this study (e.g., sprain or strain of lower limb)
• Have documented medical conditions (i.e., hypertension, asthma, heart disease, diabetes) or exhibit signs and symptoms of medical conditions
• Taking any medication that would interfere with the interpretation of our results. These include, but are not limited to, anti-inflammatory drugs, antibiotics, anti-hypertensives, and any medicine controlling the digestive system.

Sponsors & Collaborators

• Drexel University: lead

Study Sites (1)

Drexel University - Health Sciences Building

Philadelphia, Pennsylvania, 19102, United States

RECRUITING

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2024
• First Posted: February 23, 2024
• Study Start: March 6, 2024
• Primary Completion: June 1, 2025
• Study Completion: August 1, 2025
• Last Updated: November 22, 2024

Record last verified: 2024-11

Locations

US (1)